Skip to main content
SpringerLink
Log in

Antiplatelet Agents, Anticoagulants, Factor Xa Inhibitors, and Thrombin Inhibitors

  • Chapter
  • First Online:
Cardiac Drug Therapy

Part of the book series: Contemporary Cardiology ((CONCARD))

  • 3476 Accesses

Abstract

Antiplatelet agents are used in virtually all patients with coronary heart disease (CHD). Aspirin, the pioneer hallmark agent, is of proven value for the management of:

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • ARISTOTLE, Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.

    Article  CAS  PubMed  Google Scholar 

  • Aspirin Myocardial Infarction Study Research Group. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA. 1980;243:661.

    Article  Google Scholar 

  • Atrial Fibrillation Investigators. Risk factor for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from 5 randomized controlled trials. Arch Intern Med. 1994;154:1449.

    Article  Google Scholar 

  • Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone or both in unstable angina. N Engl J Med. 1986;313:1369.

    Article  Google Scholar 

  • CHARISMA Investigators: Bhat DL, Keith AA, Fox KAA, Hacke W, for the CHARISMA Investigators. Prevention of atherothrombotic events. N Engl J Med. 2006;354:1706–17.

    Google Scholar 

  • Clarke RJ, Mago G, Fitzgerald G, et al. Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation. 1991;83:1510.

    Article  CAS  PubMed  Google Scholar 

  • Coller BS. Blockade of platelet GP IIb/IIIa receptors as an antithrombotic strategy. Circulation. 1995;92:2373–80.

    Article  CAS  PubMed  Google Scholar 

  • COMMIT-2 (Clopidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1607–21.

    Google Scholar 

  • Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51 [Erratum, N Engl J Med 2010;363:1877.].

    Article  CAS  PubMed  Google Scholar 

  • Cox D, Maree AO, Dooley M, et al. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke. 2006;37:2153–8.

    Article  CAS  PubMed  Google Scholar 

  • Craven LL. Experiences with aspirin (acetylsalicylic acid) in the non-specific prophylaxis of coronary thrombosis. Miss Valley Med J. 1953;75:38.

    CAS  PubMed  Google Scholar 

  • Davies MJ, Thomas A. Thrombosis and acute coronary artery lesions in sudden cardiac ischemic death. N Engl J Med. 1984;310:1137.

    Article  CAS  PubMed  Google Scholar 

  • DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 1980;303:897.

    Article  CAS  PubMed  Google Scholar 

  • Elwood PC, Cochrane AL, Burr ML, et al. A randomized controlled trial of acetylsalicylic acid in the secondary prevention of mortality from myocardial infarction. BMJ. 1974;1:436.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Fields WS, Lemak NA, Frankowski RF, et al. Controlled trial of aspirin in cerebral ischemia. Stroke. 1977;8:301.

    Article  CAS  PubMed  Google Scholar 

  • Gage BF Can we rely on RE-LY? NEJM 2009;361:1200–1202.

    Google Scholar 

  • Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol. 2008;51:1829–43.

    Article  CAS  PubMed  Google Scholar 

  • Gebel Jr JM. Secondary stroke prevention with antiplatelet therapy with emphasis on the cardiac patient. A neurologist’s view. J Am Coll Cardiol. 2005;37:2059–65.

    Google Scholar 

  • Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009;120:2577–85.

    Article  CAS  PubMed  Google Scholar 

  • Halperin JL, Hankey GJ, Wojdyla et al., on behalf of the ROCKET AF Steering Committee and Investigators. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation. Circulation. 2014;130:138–146

    Google Scholar 

  • Halverson S, Andreotti F, ten Berg HM, et al. Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European society of cardiology working group on thrombosis. J Am Coll Cardiol. 2014;64(3):319–27.

    Article  Google Scholar 

  • Hobl E, Stimlfl T, Ebner J, et al. morphine decreases clopidogrel concentrations and effects. A randomized double—blind placebo-controlled trial. J Am Coll Cardiol. 2014;63(7):630–5.

    Article  CAS  PubMed  Google Scholar 

  • HORIZONS-AMI, Stone GW, Witzenbichler B, Guagliumi G, et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (final 3-year results from a multicentre, randomised controlled trial. Lancet. 2011;377(9784):2193–204.

    Article  CAS  PubMed  Google Scholar 

  • Hylek EM, Held C, Alexander JH, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin. The ARISTOTLE Trial (Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation) Predictors, characteristics, and clinical outcomes. J Am Coll Cardiol. 2014;63(20):2141–7.

    Article  PubMed  Google Scholar 

  • ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988a;2:349–50.

    Google Scholar 

  • Juul-Moller S, Edvardsson N, Jhnmatz B, et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet. 1992;40:1421.

    Article  Google Scholar 

  • Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180:713–8.

    Article  PubMed Central  PubMed  Google Scholar 

  • Kapoor JR. Enteric coating is a possible cause of aspirin resistance. J Am Coll Cardiol. 2008;52:1276–7.

    Article  PubMed  Google Scholar 

  • Kastrati A, Neumann F-J, Schulz S, for the ISAR-REACT 4 Trial Investigators, et al. Abciximab and heparin versus bivalirudin for non–ST-elevation myocardial infarction. N Engl J Med. 2011;365:1980–9.

    Article  PubMed  Google Scholar 

  • Kempin SJ. Warfarin resistance caused by broccoli. N Engl J Med. 1983;308:1229.

    Article  CAS  PubMed  Google Scholar 

  • Kotsia A, Brilakis ES, Held C, et al. Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2014;168(1):68–75.e2.

    Article  CAS  PubMed  Google Scholar 

  • Lev EI, Patel RT, Maresh KJ. The role of dual drug resistance. J Am Coll Cardiol. 2006;47:27–33.

    Google Scholar 

  • Lewis HD, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a veterans administration cooperative study. N Engl J Med. 1983;309:396.

    Article  PubMed  Google Scholar 

  • Maree AO, Curtin RJ, Dooley M, et al. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol. 2005;46:1258–63.

    Article  CAS  PubMed  Google Scholar 

  • Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9–19.

    Article  CAS  PubMed  Google Scholar 

  • Mehta SR, Granger CB, Boden WE, TIMACS, et al. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med. 2009;360:2165–75.

    Article  CAS  PubMed  Google Scholar 

  • O’Donoghue M, Antman EM, Braunwald E, et al. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON–TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38) analysis. J Am Coll Cardiol. 2009;54:678–85. (TRITON–TIMI 38).

    Google Scholar 

  • Patrono C, Wood AJJ. Aspirin as an anti-platelet drug. N Engl J Med. 1994;330:1287.

    Article  CAS  PubMed  Google Scholar 

  • PLATO, Cannon CP, Harrington RA, James S, et al. for the platelet inhibition and patient Outcomes investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes: a randomised double-blind study. Lancet. 2010;375(9711):283–93.

    Article  CAS  PubMed  Google Scholar 

  • Resnekov L, Chekiak J, Hirsh J, et al. Antithrombotic agents in coronary artery disease. Chest. 1989;95:528.

    Article  Google Scholar 

  • ROCKET AF, Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365: 883–891.

    Google Scholar 

  • Sherman CT, Litrack F, Grundfest W, et al. Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med. 1986;315:913.

    Article  CAS  PubMed  Google Scholar 

  • The ESPS Group. The European Stroke Prevention Study. Principal end points. Lancet. 1987;2:1352.

    Google Scholar 

  • TRITON-TIMI 38 Investigators, Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction double-blind, randomised controlled trial. Lancet. 2009;373(9665):723–31.

    Article  CAS  PubMed  Google Scholar 

  • Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J. 2008; 29:21–30.

    Article  CAS  PubMed  Google Scholar 

  • Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation. 2007;116:2923–32.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Ottawa The Ottawa Hospital, Ottawa, ON, Canada

    M. Gabriel Khan MD, FRCPC, FRCP (London), FACC

Authors
  1. M. Gabriel Khan MD, FRCPC, FRCP (London), FACC
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Khan, M.G. (2015). Antiplatelet Agents, Anticoagulants, Factor Xa Inhibitors, and Thrombin Inhibitors. In: Cardiac Drug Therapy. Contemporary Cardiology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-962-4_19

Download citation

  • DOI: https://doi.org/10.1007/978-1-61779-962-4_19

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61779-961-7

  • Online ISBN: 978-1-61779-962-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation